Novel recombinant antibodies from murine antibody IOR C5 produced by the hybridoma
deposited with the ECCC 97061101. The recombinant antibodies were obtained using
recombinant DNA technology and are characterized in that they recognize antigen
ior C2. The recombinant antibodies are specifically chimeric antibody, humanized
antibody, and single chain Fv fragment. The chimeric antibody contains the variable
domains of the murine immunoglobuline and the constant regions of the human immunoglobuline.
The humanized antibody contains the constant regions of human immunoglobuline and
has been specifically modified in the murine frameworks regions (FRs) and within
the latter, in those areas that may result in an antigenic site for cells T. The
Fv fragment contains the variable domains of murine immunoglobuline. The invention
also relates to the utilization of recombinant antibodies derived from murine antibody
ior C5 in the diagnosis and therapy of colorectal tumors, the metastasis thereof
and recurrences.
